Cargando…

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing

Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing. Janus kinase (JAK) inhibition with tofacitinib has been demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaber, Timo, Brinkman, Antonia Clara Katharina, Pienczikowski, Justyna, Diesing, Karoline, Damerau, Alexandra, Pfeiffenberger, Moritz, Lang, Annemarie, Ohrndorf, Sarah, Burmester, Gerd-Rüdiger, Buttgereit, Frank, Hoff, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037633/ https://www.ncbi.nlm.nih.gov/pubmed/32013232 http://dx.doi.org/10.3390/ijms21030865

Ejemplares similares

A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro
por: Damerau, Alexandra, et al.
Publicado: (2020)

Fracture Healing Research—Shift towards In Vitro Modeling?
por: Pfeiffenberger, Moritz, et al.
Publicado: (2021)

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
por: Gaber, Timo, et al.
Publicado: (2018)

Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes
por: Krauss, Pierre-Louis, et al.
Publicado: (2021)

Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model
por: Pfeiffenberger, Moritz, et al.
Publicado: (2019)

Age-related increase of mitochondrial content in human memory CD4+ T cells contributes to ROS-mediated increased expression of proinflammatory cytokines
por: Chen, Yuling, et al.
Publicado: (2022)

JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration
por: Damerau, Alexandra, et al.
Publicado: (2020)

A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients
por: Hoff, Paula, et al.
Publicado: (2017)

Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia
por: Fangradt, Monique, et al.
Publicado: (2012)

Thiamazol-induzierte Arthritis
por: Brinkman, Antonia, et al.
Publicado: (2020)

Inhibition of Complex I of the Respiratory Chain, but Not Complex III, Attenuates Degranulation and Cytokine Secretion in Human Skin Mast Cells
por: Buttgereit, Thomas, et al.
Publicado: (2022)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2020)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?
por: Buttgereit, Frank, et al.
Publicado: (2015)

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
por: Kim, Sa Rang, et al.
Publicado: (2018)

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
por: Gwak, Eun Hye, et al.
Publicado: (2020)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

Follow-Up Comparison of Fluorescence Optical Imaging With Musculoskeletal Ultrasound for Early Detection of Psoriatic Arthritis
por: Büttner, Juliane, et al.
Publicado: (2022)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
por: Al-Hashimi, Leith, et al.
Publicado: (2023)

Journey into Bone Models: A Review
por: Scheinpflug, Julia, et al.
Publicado: (2018)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
por: Talty, Ronan, et al.
Publicado: (2021)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cells
por: Buttgereit, Frank, et al.
Publicado: (2021)

A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptors
por: Gaber, Timo, et al.
Publicado: (2022)

Digital health information on autoinflammatory diseases: a YouTube quality analysis
por: Sasse, Mareen, et al.
Publicado: (2022)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
por: Aleisa, Ahmad I., et al.
Publicado: (2020)

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
por: Hasni, Sarfaraz A., et al.
Publicado: (2021)

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period
por: Glimm, Anne-Marie, et al.
Publicado: (2019)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Idiopathic erythema multiforme: Evidence of underlying Janus kinase–signal transducer and activator of transcription activation and successful treatment with tofacitinib
por: Damsky, William, et al.
Publicado: (2016)

Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
por: Sadeghi, Sara, et al.
Publicado: (2022)

The association between rheumatoid arthritis and periodontal disease
por: Detert, Jacqueline, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q9cfpe1fgr47fdbtif7ge7t9k9